Top

Published in:

01-08-2013 | Sarcomas (SR Patel, Section Editor)

Novel Pathways and Molecular Targets for the Treatment of Sarcoma

Authors: Ashley E. Frith, Angela C. Hirbe, Brian A. Van Tine

Published in: Current Oncology Reports | Issue 4/2013

Abstract

Sarcomas collectively represent over 100 different subtypes of bone and soft tissue tumors of mesenchymal origin. The low response rate to cytotoxic chemotherapies has necessitated the need for development of either histologically driven or pathway-specific targeted therapies. As our understanding of the molecular mechanisms driving certain subtypes is rapidly advancing, the number of targeted therapies is also increasing. Recently identified novel druggable targets include the MDM2 amplifications in well-differentiated and dedifferentiated liposarcomas, the new translocation NAB2:STAT6 of solitary fibrous tumors, the angiopoeitin-TIE2 pathway in angiosarcoma, the suppression of Mcl1 in X:18/synovial sarcomas, the mTOR pathway in malignant peripheral nerve sheath tumors, CDK4 in alveolar rhabdomyosarcoma, cMET regulation in alveolar soft parts sarcoma, the metabolic abnormalities in wild-type/SHD GIST, and the lack of argininosuccinate synthetase 1 expression seen in most sarcomas. It is through a fundamental understanding of sarcoma biology that clinical trials based on molecular targets can be developed.

•• von Mehren M, Benjamin RS, Bui MM, et al. Soft tissue sarcoma, version 2.2012: featured updates to the NCCN guidelines. Journal of the National Comprehensive Cancer Network 2012;10:951-60. The current treatment guidelines for sarcoma are detailed here and actively updated by committee.

Jemal A, Siegel R, Xu J, et al. Cancer Statistics, 2010. CA Cancer J Clin. 2010;60:277–300.PubMedCrossRef

• Rajendra R, Pollack SM, Jones RL. Management of gastrointestinal stromal tumors. Future Oncology 2013;9:193-206. This is a recent review on the management of GIST.

Jones B, Komarnitsky P, Miller GT, et al. Anticancer activity of stabilized palifosfamide in vivo: schedule effects, oral bioavailability, and enhanced activity with docetaxel and doxorubicin. Anti-Cancer Drugs. 2012;23:173–84.PubMedCrossRef

Ganjoo KN, Cranmer LD, Butrynski JE, et al. A phase I study of the safety and pharmacokinetics of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma. Oncology. 2011;80:50–6.PubMedCrossRef

Kindblom LG. Lipomatous tumors-how we have reached our present views, what controversies remain and why we still face diagnostic problems: a tribute to Dr Franz Enzinger. Adv Anat Pathol. 2006;13:279–85.PubMedCrossRef

Jones RL, Fisher C, Al-Muderis O, et al. Differential sensitivity of liposarcoma subtypes to chemotherapy. Eur J Cancer. 2005;41:2853–60.PubMedCrossRef

• Conyers R, Young S, Thomas DM. Liposarcoma: molecular genetics and therapeutics. Sarcoma 2011;2011:483154. This is a current in depth review of liposarcoma.

Rieker RJ, Weitz J, Lehner B, et al. Genomic profiling reveals subsets of dedifferentiated liposarcoma to follow separate molecular pathways. Virchows Arch. 2010;456:277–85.PubMedCrossRef

10.

Pedeutour F, Forus A, Coindre JM, et al. Structure of the supernumerary ring and giant rod chromosomes in adipose tissue tumors. Genes Chromosomes Cancer. 1999;24:30–41.PubMedCrossRef

11.

Dei Tos AP, Doglioni C, Piccinin S, et al. Coordinated expression and amplification of the MDM2, CDK4, and HMGI-C genes in atypical lipomatous tumours. J Pathol. 2000;190:531–6.PubMedCrossRef

12.

•• Pei D, Zhang Y, Zheng J. Regulation of p53: a collaboration between Mdm2 and Mdmx. Oncotarget 2012;3:228-35. Review of the interactione between MDM2, MDMX and its regulation of p53.

13.

Vassilev LT. MDM2 inhibitors for cancer therapy. Trends Mol Med. 2007;13:23–31.PubMedCrossRef

14.

Ray-Coquard I, Blay JY, Italiano A, et al. Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. Lancet Oncol. 2012;13:1133–40.PubMedCrossRef

15.

Shangary S, Qin D, McEachern D, et al. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci U S A. 2008;105:3933–8.PubMedCrossRef

16.

Patton JT, Mayo LD, Singhi AD, et al. Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3. Cancer Res. 2006;66:3169–76.PubMedCrossRef

17.

Wade M, Wong ET, Tang M, et al. Hdmx modulates the outcome of p53 activation in human tumor cells. J Biol Chem. 2006;281:33036–44.PubMedCrossRef

18.

Vassilev LT. p53 Activation by small molecules: application in oncology. J Med Chem. 2005;48:4491–9.PubMedCrossRef

19.

Xia M, Knezevic D, Tovar C, et al. Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation. Cell Cycle. 2008;7:1604–12.PubMedCrossRef

20.

Graves B, Thompson T, Xia M, et al. Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization. Proc Natl Acad Sci U S A. 2012;109:11788–93.PubMedCrossRef

21.

Park MS, Araujo DM. New insights into the hemangiopericytoma/solitary fibrous tumor spectrum of tumors. Curr Opin Oncol. 2009;21:327–31.PubMedCrossRef

22.

Penel N, Amela EY, Decanter G, et al. Solitary fibrous tumors and so-called hemangiopericytoma. Sarcoma. 2012;2012:690251.PubMedCrossRef

23.

•• Robinson DR, Wu YM, Kalyana-Sundaram S, et al. Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing. Nat Genet. 2013;45:180-5. The discovery of the NAB2:STAT6 translocation in SFT.

24.

Bhattacharyya S, Fang F, Tourtellotte W, et al. Egr-1: new conductor for the tissue repair orchestra directs harmony (regeneration) or cacophony (fibrosis). J Pathol. 2013;229:286–97.PubMedCrossRef

25.

Goenka S, Kaplan MH. Transcriptional regulation by STAT6. Immunol Res. 2011;50:87–96.PubMedCrossRef

26.

Stacchiotti S, Negri T, Palassini E, et al. Sunitinib malate and figitumumab in solitary fibrous tumor: patterns and molecular bases of tumor response. Mol Cancer Ther. 2010;9:1286–97.PubMedCrossRef

27.

Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279:577–80.PubMedCrossRef

28.

Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol. 2004;22:3813–25.PubMedCrossRef

29.

Verweij J, van Oosterom A, Blay JY, et al. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer. 2003;39:2006–11.PubMedCrossRef

30.

Belinsky MG, Skorobogatko YV, Rink L, et al. High density DNA array analysis reveals distinct genomic profiles in a subset of gastrointestinal stromal tumors. Genes Chromosomes Cancer. 2009;48:886–96.PubMedCrossRef

31.

Carney JA, Stratakis CA. Familial paraganglioma and gastric stromal sarcoma: a new syndrome distinct from the Carney triad. Am J Med Genet. 2002;108:132–9.PubMedCrossRef

32.

Stratakis CA, Carney JA. The triad of paragangliomas, gastric stromal tumours and pulmonary chondromas (Carney triad), and the dyad of paragangliomas and gastric stromal sarcomas (Carney-Stratakis syndrome): molecular genetics and clinical implications. J Intern Med. 2009;266:43–52.PubMedCrossRef

33.

•• Janeway KA, Kim SY, Lodish M, et al. Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci U S A 2011;108:314-8. Defines the defects in succinate dehydrogenase in SDH GIST.

34.

Miettinen M, Killian JK, Wang ZF, et al. Immunohistochemical loss of succinate dehydrogenase subunit A (SDHA) in gastrointestinal stromal tumors (GISTs) signals SDHA germline mutation. Am J Surg Pathol. 2013;37:234–40.PubMedCrossRef

35.

Briere JJ, Favier J, Benit P, et al. Mitochondrial succinate is instrumental for HIF1alpha nuclear translocation in SDHA-mutant fibroblasts under normoxic conditions. Hum Mol Genet. 2005;14:3263–9.PubMedCrossRef

36.

Pollard PJ, Briere JJ, Alam NA, et al. Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. Hum Mol Genet. 2005;14:2231–9.PubMedCrossRef

37.

Melillo G. Targeting hypoxia cell signaling for cancer therapy. Cancer Metastasis Rev. 2007;26:341–52.PubMedCrossRef

38.

Young RJ, Brown NJ, Reed MW, et al. Angiosarcoma. Lancet Oncol. 2010;11:983–91.PubMedCrossRef

39.

Rouhani P, Fletcher CD, Devesa SS, et al. Cutaneous soft tissue sarcoma incidence patterns in the U.S.: an analysis of 12,114 cases. Cancer. 2008;113:616–27.PubMedCrossRef

40.

Abraham JA, Hornicek FJ, Kaufman AM, et al. Treatment and outcome of 82 patients with angiosarcoma. Ann Surg Oncol. 2007;14:1953–67.PubMedCrossRef

41.

Mark RJ, Poen JC, Tran LM, et al. Angiosarcoma. A report of 67 patients and a review of the literature. Cancer. 1996;77:2400–6.PubMedCrossRef

42.

Fury MG, Antonescu CR, Van Zee KJ, et al. A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy. Cancer J. 2005;11:241–7.PubMedCrossRef

43.

Nagano T, Yamada Y, Ikeda T, et al. Docetaxel: a therapeutic option in the treatment of cutaneous angiosarcoma: report of 9 patients. Cancer. 2007;110:648–51.PubMedCrossRef

44.

Penel N, Bui BN, Bay JO, et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol. 2008;26:5269–74.PubMedCrossRef

45.

Rosen A, Thimon S, Ternant D, et al. Partial response to bevacizumab of an extensive cutaneous angiosarcoma of the face. Br J Dermatol. 2010;163:225–7.PubMed

46.

De Yao JT, Sun D, Powell AT, et al. Scalp angiosarcoma remission with bevacizumab and radiotherapy without surgery: a case report and review of the literature. Sarcoma. 2011;2011:160369.PubMed

47.

• Agulnik M, Yarber JL, Okuno SH, et al. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Annals of Oncology: Official Journal of the European Society for Medical Oncology / ESMO 2013;24:257-63. Open label trial demonstrating a low response rate to VEGF targeting in angiosarcoma.

48.

• Huang H, Bhat A, Woodnutt G, et al. Targeting the ANGPT-TIE2 pathway in malignancy. Nat Rev Cancer 2010;10:575-85. Review of the ANGPT-TIE2 pathway.

49.

Coxon A, Bready J, Min H, et al. Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody. Mol Cancer Ther. 2010;9:2641–51.PubMedCrossRef

50.

Antonescu CR, Yoshida A, Guo T, et al. KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors. Cancer Res. 2009;69:7175–9.PubMedCrossRef

51.

Brown LF, Dezube BJ, Tognazzi K, et al. Expression of Tie1, Tie2, and angiopoietins 1, 2, and 4 in Kaposi's sarcoma and cutaneous angiosarcoma. Am J Pathol. 2000;156:2179–83.PubMedCrossRef

52.

Oliner J, Min H, Leal J, et al. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell. 2004;6:507–16.PubMedCrossRef

53.

Haldar M, Hancock JD, Coffin CM, et al. A conditional mouse model of synovial sarcoma: insights into a myogenic origin. Cancer Cell. 2007;11:375–88.PubMedCrossRef

54.

Do K, Doroshow JH, Kummar S. Antiangiogenic approaches for the treatment of advanced synovial sarcomas. Curr Opin Oncol. 2012;24:425–30.PubMedCrossRef

55.

Smith ME, Fisher C, Wilkinson LS, et al. Synovial sarcoma lack synovial differentiation. Histopathology. 1995;26:279–81.PubMedCrossRef

56.

Fisher C. Synovial sarcoma: ultrastructural and immunohistochemical features of epithelial differentiation in monophasic and biphasic tumors. Hum Pathol. 1986;17:996–1008.PubMedCrossRef

57.

Su L, Sampaio AV, Jones KB, et al. Deconstruction of the SS18-SSX fusion oncoprotein complex: insights into disease etiology and therapeutics. Cancer Cell. 2012;21:333–47.PubMedCrossRef

58.

Nagao K, Ito H, Yoshida H. Chromosomal translocation t(X;18) in human synovial sarcomas analyzed by fluorescence in situ hybridization using paraffin-embedded tissue. Am J Pathol. 1996;148:601–9.PubMed

59.

•• Jones KB, Su L, Jin H, et al. SS18-SSX2 and the mitochondrial apoptosis pathway in mouse and human synovial sarcomas. Oncogene 2012;1-7. Demonstration of the suppression of Mcl1 by the X:18 fusion protein.

60.

de Bruijn DR, Baats E, Zechner U, et al. Isolation and characterization of the mouse homolog of SYT, a gene implicated in the development of human synovial sarcomas. Oncogene. 1996;13:643–8.PubMed

61.

Thaete C, Brett D, Monaghan P, et al. Functional domains of the SYT and SYT-SSX synovial sarcoma translocation proteins and co-localization with the SNF protein BRM in the nucleus. Hum Mol Genet. 1999;8:585–91.PubMedCrossRef

62.

Perani M, Ingram CJ, Cooper CS, et al. Conserved SNH domain of the proto-oncoprotein SYT interacts with components of the human chromatin remodelling complexes, while the QPGY repeat domain forms homo-oligomers. Oncogene. 2003;22:8156–67.PubMedCrossRef

63.

Hirakawa N, Naka T, Yamamoto I, et al. Overexpression of bcl-2 protein in synovial sarcoma: a comparative study of other soft tissue spindle cell sarcomas and an additional analysis by fluorescence in situ hybridization. Hum Pathol. 1996;27:1060–5.PubMedCrossRef

64.

Yecies D, Carlson NE, Deng J, et al. Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. Blood. 2010;115:3304–13.PubMedCrossRef

65.

Tahir SK, Wass J, Joseph MK, et al. Identification of expression signatures predictive of sensitivity to the Bcl-2 family member inhibitor ABT-263 in small cell lung carcinoma and leukemia/lymphoma cell lines. Mol Cancer Ther. 2010;9:545–57.PubMedCrossRef

66.

Yang J, Zhang W. Genomic and molecular characterization of IGF1R as a promising therapeutic target in malignant peripheral nerve sheath tumor. Available at http://sarcomahelp.org/research/mpnst-IGF1R.html. Accessed March 2013.

67.

Kolberg M, Holand M, Agesen TH, et al. Survival meta-analyses for >1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1. Neuro Oncol. 2013;15:135–47.PubMedCrossRef

68.

Guha A, Lau N, Huvar I, et al. Ras-GTP levels are elevated in human NF1 peripheral nerve tumors. Oncogene. 1996;12:507–13.PubMed

69.

Johannessen CM, Reczek EE, James MF, et al. The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci U S A. 2005;102:8573–8.PubMedCrossRef

70.

Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 2004;18:1926–45.PubMedCrossRef

71.

Raynaud FI, Eccles S, Clarke PA, et al. Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res. 2007;67:5840–50.PubMedCrossRef

72.

Marshall AD, Grosveld GC. Alveolar rhabdomyosarcoma - The molecular drivers of PAX3/7-FOXO1-induced tumorigenesis. Skelet Muscle. 2012;2:25.PubMedCrossRef

73.

Dantonello TM, Int-Veen C, Schuck A, et al. Survival following disease recurrence of primary localized alveolar rhabdomyosarcoma. Pediatr Blood Cancer 2013, In press.

74.

Sorensen PH, Lynch JC, Qualman SJ, et al. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group. J Clin Oncol. 2002;20:2672–9.PubMedCrossRef

75.

Calhabeu F, Hayashi S, Morgan JE, et al. Alveolar rhabdomyosarcoma-associated proteins PAX3/FOXO1A and PAX7/FOXO1A suppress the transcriptional activity of MyoD-target genes in muscle stem cells. Oncogene. 2013;32:651–62.PubMedCrossRef

76.

Charytonowicz E, Matushansky I, Domenech JD, et al. PAX7-FKHR fusion gene inhibits myogenic differentiation via NF-kappaB upregulation. Clin Transl Oncol. 2012;14:197–206.PubMedCrossRef

77.

•• Liu L, Wu J, Ong S, Chen T. Cyclin-dependent kinase 4 phosphorylates and positively regulates PAX3-FOX01 in human alveolar rhabdomyosarcoma cells. PLoS One 2013;8:e58193. Demonstrated the regulation of PAX3:FOXO1 by CDK4.

78.

Flaherty K, Lorusso P, Demichele A, et al. Phase I, dose escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clin Cancer Res. 2012;18:568–76.PubMedCrossRef

79.

Gelbert L, Cai S, Lin X, et al. Identification and characterization of LY2835219: a potent oral inhibitor of the cyclin-dependent kinases 4 and 6 (CDK4/6) with broad in vivo antitumor activity [abstract B233]. Molecular Cancer Therapeutics 2011. doi:10.1158/1535-7163.TARG-11-B233.

80.

Hirte H, Raghunadharao D, Baetz T, et al. A phase I study of the selective cyclin dependent kinase inhibitor P276-00 in patients with advanced refactory neoplasms [abstract 4368]. AACR Meeting Abstracts April 2007.

81.

Stacchiotti S, Tamborini E, Marrari A, et al. Response to sunitinib malate in advanced alveolar soft part sarcoma. Clin Cancer Res. 2009;15:1096–104.PubMedCrossRef

82.

Ladanyi M, Lui MY, Antonescu CR, et al. The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25. Oncogene. 2001;20:48–57.PubMedCrossRef

83.

Tsuda M, Davis IJ, Argani P, et al. TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition. Cancer Res. 2007;67:919–29.PubMedCrossRef

84.

Kobayashi E, Masuda M, Nakayama R, et al. Reduced argininosuccinate synthetase is a predictive biomarker for the development of pulmonary metastasis in patients with osteosarcoma. Mol Cancer Ther. 2010;9:535–44.PubMedCrossRef

85.

•• Boone P, Weich D, Shunqiang L, et al. Simultaneous autophagy induction and ihibition induces cell death through necroptosis in sarcomas that lack argininosuccinate synthesase 1 expression. [paper #3]. Presented at the 17th Annual Connective Tissue Oncology Society Meeting. Prague, Czech Republic. November 14–17, 2012. Demonstration that ASS1 is not expressed in the majority of sarcomas.

Title: Novel Pathways and Molecular Targets for the Treatment of Sarcoma
Authors: Ashley E. Frith
Angela C. Hirbe
Brian A. Van Tine
Publication date: 01-08-2013
Publisher: Springer US
Published in: Current Oncology Reports / Issue 4/2013
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI: https://doi.org/10.1007/s11912-013-0319-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2013

The Adolescent and Young Adult with Cancer: State of the Art—Brain Tumor

The Adolescent and Young Adult with Cancer: State of the Art - Bone Tumors

Current and Future Treatments for Malignant Pheochromocytoma and Sympathetic Paraganglioma

The Adolescent and Young Adult With Cancer: State of the Art—Epithelial Cancer

Cancer in Adolescents and Young Adults in Countries with Limited Resources

The Adolescent and Young Adult with Cancer: State of the Art-- Acute Leukemias

Keynote webinar | Spotlight on antibody–drug conjugates in cancer